Durata Therapeutics
Branford
About Durata Therapeutics
Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners. Durata is focused on Vicuron’s antibiotic drug candidate, dalbavancin. Its product portfolio also includes two preclinical antibiotic programs while Pfizer will retain the marketed anti-fungal agent, EraxisTM, which was formerly owned by Vicuron.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $70.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2013)
- Ticker: nasdaq:DRTX
- Website: duratatherapeutics.com
- Phone: +1 312-219-7000
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/durata-therapeutics-1123315 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.